Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
| Application |
Recommended Dilution |
| 1:100-1:200 |
|
Note :
IHC-P
Manual staining : Heat-induced antigen retrieval for 5 minutes in an autoclave at 121ºC in pH 9.0 Tris-EDTA-based Target Retrieval Solution buffer. Based on testing result, pH 9.0 showed a strongest staining pattern. However, pH 9.0 results in only a slight reduction of the staining intensity as compared to pH 9.0. Therefore, the pH 7.8 was an optimal for manual staining because of the better tissue preservation at pH 7.8 than at pH 9.0.
This antibody has been validated by Autostainer including Agilent/Dako - Autostainer Link 48 and BOND RX - Leica. The detailed steps by Autostainer please refer to the protocol.
|
Not tested in other applications.
Positive Control
Pancreas: at least a moderate staining is expected in islets of Langerhans
Negative Control
Pancreas: staining should be absent in acinar cells, Normal cervix uteri: p16 staining should be absent in epithelial cells (in some cases, few cells may show weak staining)
Form
Liquid
Buffer
PBS, 0.05% BSA (Please contact us for PBS only format)
Preservative
0.05% sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
0.2 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Recombinant full-length human p16INK4a protein
Purification
Protein A/G purified
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
cyclin dependent kinase inhibitor 2A , ARF , CDK4I , CDKN2 , CMM2 , INK4 , INK4A , MLM , MTS-1 , MTS1 , P14 , P14ARF , P16 , P16-INK4A , P16INK4 , P16INK4A , P19 , P19ARF , TP16
Cellular Localization
Cytoplasm , Nucleus , nucleoplasm , Nucleolus
Background
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
Database
Research Area
![Anti-CDKN2A / p16INK4a antibody [MSVA-016R] HistoMAX™ used in IHC (Paraffin sections) (IHC-P). GTX04442](/upload/website/prouct_img/small/GTX04442/GTX04442_20230728_IHC-P_89_23072722_864.webp "Anti-CDKN2A / p16INK4a antibody [MSVA-016R] HistoMAX™ used in IHC (Paraffin sections) (IHC-P). GTX04442")
![Anti-CDKN2A / p16INK4a antibody [MSVA-016R] HistoMAX™ used in IHC (Paraffin sections) (IHC-P). GTX04442](/upload/website/prouct_img/small/GTX04442/GTX04442_20230728_IHC-P_219_23072722_902.webp "Anti-CDKN2A / p16INK4a antibody [MSVA-016R] HistoMAX™ used in IHC (Paraffin sections) (IHC-P). GTX04442")
![Anti-CDKN2A / p16INK4a antibody [MSVA-016R] HistoMAX™ used in IHC (Paraffin sections) (IHC-P). GTX04442](/upload/website/prouct_img/small/GTX04442/GTX04442_20230728_IHC-P_349_23072723_215.webp "Anti-CDKN2A / p16INK4a antibody [MSVA-016R] HistoMAX™ used in IHC (Paraffin sections) (IHC-P). GTX04442")
![Anti-CDKN2A / p16INK4a antibody [MSVA-016R] HistoMAX™ used in IHC (Paraffin sections) (IHC-P). GTX04442](/upload/website/prouct_img/normal/GTX04442/GTX04442_20230728_IHC-P_89_23072722_864.webp "Anti-CDKN2A / p16INK4a antibody [MSVA-016R] HistoMAX™ used in IHC (Paraffin sections) (IHC-P). GTX04442")
![Anti-CDKN2A / p16INK4a antibody [MSVA-016R] HistoMAX™ used in IHC (Paraffin sections) (IHC-P). GTX04442](/upload/website/prouct_img/normal/GTX04442/GTX04442_20230728_IHC-P_219_23072722_902.webp "Anti-CDKN2A / p16INK4a antibody [MSVA-016R] HistoMAX™ used in IHC (Paraffin sections) (IHC-P). GTX04442")
![Anti-CDKN2A / p16INK4a antibody [MSVA-016R] HistoMAX™ used in IHC (Paraffin sections) (IHC-P). GTX04442](/upload/website/prouct_img/normal/GTX04442/GTX04442_20230728_IHC-P_349_23072723_215.webp "Anti-CDKN2A / p16INK4a antibody [MSVA-016R] HistoMAX™ used in IHC (Paraffin sections) (IHC-P). GTX04442")